Occlutech was founded in Germany in 2003, and has since developed into one of the world´s leading suppliers in the area of structural heart disease with products and projects for; congenital defects, stroke prevention, and heart failure.
The company´s products are sold in over 80 countries globally and the total number of implantations is approaching 100.000, setting the highest standards regarding quality, outcomes and patient safety.
Occlutech maintains direct sales and clinical support operations to hospitals and physicians in Canada and Europe. Throughout the rest of the world the company works through qualified distribution partners, many of them shareholders and long-term partners.
Occlutech operates R&D and manufacturing facilities at its original site in Jena, Germany and at an additional site in Istanbul, Turkey. From Helsingborg, Sweden the company runs its global marketing support, customer service and manages global sales.
Products Portfolio
Occlutech’s current and future products are based on a strong technology and patent foundation. The unique, patented braiding technology allows Occlutech to create products that are remarkably different, adding significant value to cardiac implants and occlusion products. The unique flexible braiding allows Occlutech to create products that can be implanted in a high rate of patients, avoiding surgery, while minimizing potentially fatal complications from e.g. erosion. With around 40,000 implants, Occlutech has a product performance track record second to none.
